News | July 27, 2021
Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr
The US business faced price erosion due to increased competition.
The US business faced price erosion due to increased competition.
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The company plans to enter the EU markets in FY22
India sales grew 23.5% YoY with consolidation of Wockhardt products
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
The jump in profit is due to the better performance of the API business.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)